Omada Health, Inc. provides a range of virtual care programs in the United States. The company is headquartered in San Francisco, California.
| Revenue (TTM) | $333.04M |
| Gross Profit (TTM) | $235.42M |
| EBITDA | $13.09M |
| Operating Margin | 5.28% |
| Return on Equity | 5.72% |
| Return on Assets | 1.35% |
| Revenue/Share (TTM) | $5.59 |
| Book Value | $4.41 |
| Price-to-Book | 4.59 |
| Price-to-Sales (TTM) | 2.77 |
| EV/Revenue | 3.123 |
| EV/EBITDA | 91.29 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 34.20% |
| Shares Outstanding | $61.22M |
| Float | $51.68M |
| % Insiders | 2.14% |
| % Institutions | 81.39% |
Volatility is currently expanding
Three stocks are seeing unusual options activity following their quarterly earnings reports: DraftKings Inc (NASDAQ:DKNG), TransMedics Group Inc (NASDAQ:TMDX), and Omada Health Inc (NASDAQ:OMDA).
Omada Health NASDAQ: OMDA raised its full-year 2026 revenue and adjusted EBITDA outlook after reporting record quarterly revenue and net income in the third quarter, driven by enrollment and growth in its diabetes and hypertension programs.
Quarterly Revenue of $91 million and All-Time High Total Members of 1.1 million Revenue Grew 34% and Total Members Increased 36% Year over Year Raises Full Year 2026 Financial Outlook SAN FRANCISCO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Omada Health, Inc. (Nasdaq: OMDA), the virtual between-visit healthcare provider, today reported financial results for the third quarter ended September 30, 2026. Financial Highlights Revenue of $91 million, compared with total revenue of $68 million in Q3 2025 Gross margin of 76% in the third quarter, up from 66% in Q3 2025 Non-GAAP gross margin of 78% in the third quarter, up from 68% in Q3 2025 Net income of $7 million in the third quarter, compared with a net loss of $3 million in Q3 2025 Adjusted EBITDA of $12 million in the third quarter, compared with Adjusted EBITDA of $2 million in Q3 2025 Trailing 12-month revenue per Total Member grew approximately 5% year over year to $294 Cash and cash equivalents of $243 million Please see the non-GAAP Financial Measures section below and reconciliations of GAAP to non-GAAP measures at the end of this press release.
SAN FRANCISCO, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, announced it will present research at the World Obesity and Weight Management Congress (WOC 2026) in Boston showing that members of its GLP-1 Care Track lost more weight and experienced greater improvements in body composition than GLP-1 users receiving usual care. The findings were recently published in the peer-reviewed journal Diabetes, Obesity and Metabolism.
SAN FRANCISCO, Oct. 13, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual between-visit healthcare provider, today announced that it will release its third quarter 2026 results on Thursday, November 5, 2026, after market close, and host a conference call to review the results at 4:30 pm ET the same day. Conference Call Details A live audio webcast of the call will be available online at https://investors.omadahealth.com.
Omada Health, Inc. (OMDA) Analyst/Investor Day Transcript
SAN FRANCISCO, Sept. 10, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, will present its long-term financial targets at the company's inaugural Investor Day, being held today at the Four Seasons Hotel in New York, New York.
SAN FRANCISCO, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Omada Health (Nasdaq: OMDA), the virtual-first, between-visit healthcare provider, announced a new, independent cost savings model that examined the measurable clinical and economic value of Omada's GLP-1 program.1 GlobalData , a data analytics and consulting company, recently published a report estimating greater disease reduction and higher cumulative cost savings with Omada's GLP-1 solutions compared to standard care.
Omada Health (OMDA) delivered strong Q2 results, with 43% revenue growth, margin expansion, and positive adj. EBITDA, reinforcing my buy rating. OMDA's product expansion, especially in diabetes and hypertension, is driving higher revenue per member and improving customer-lifetime-value through multi-program adoption. Channel partnerships with PBMs and health plans are lowering CAC, supporting scalable growth and better unit economics, while AI initiatives further enhance operational leverage.
Omada Health NASDAQ: OMDA highlighted record second-quarter revenue and margin performance at the Canaccord Genuity Growth Conference, while outlining its strategy to expand across cardiometabolic conditions, deepen channel partnerships and use GLP-1-related demand to broaden customer relationships.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on OMDA and any ticker you trade — then tracks every position and per-strategy win rate.
